InflaRx Doses First Patient in Multicenter Phase II Clinical Trial in Cutaneous Squamous Cell Carcinoma with Vilobelimab
The Phase II clinical trial is expected to enroll approximately 70 patients at sites in Europe, the U.S. and elsewhere.
- The Phase II clinical trial is expected to enroll approximately 70 patients at sites in Europe, the U.S. and elsewhere.
- The study will investigate two independent arms: vilobelimab alone and vilobelimab in combination with pembrolizumab.
- Dr. Korinna Pilz, Global Head of Clinical Research and Development at InflaRx, said: We are pleased to initiate the first clinical trial to evaluate vilobelimab in cancer.
- Approximately 300 people have been treated with vilobelimab in clinical trials, and the antibody has been shown to be well tolerated.